Boston Trust Walden Corp Boosts Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Boston Trust Walden Corp lifted its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 54.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 682,616 shares of the biopharmaceutical company's stock after purchasing an additional 239,321 shares during the quarter. Boston Trust Walden Corp owned about 0.54% of Halozyme Therapeutics worth $39,073,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. TD Asset Management Inc increased its position in shares of Halozyme Therapeutics by 28.1% during the 1st quarter. TD Asset Management Inc now owns 2,541,266 shares of the biopharmaceutical company's stock worth $103,379,000 after purchasing an additional 557,350 shares during the last quarter. Norden Group LLC increased its position in shares of Halozyme Therapeutics by 1,817.3% during the first quarter. Norden Group LLC now owns 167,284 shares of the biopharmaceutical company's stock valued at $6,805,000 after acquiring an additional 158,559 shares during the last quarter. CANADA LIFE ASSURANCE Co raised its stake in shares of Halozyme Therapeutics by 29.5% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 130,856 shares of the biopharmaceutical company's stock valued at $5,321,000 after acquiring an additional 29,845 shares during the period. Swedbank AB acquired a new position in shares of Halozyme Therapeutics in the 1st quarter worth approximately $13,927,000. Finally, Mizuho Markets Americas LLC lifted its holdings in shares of Halozyme Therapeutics by 2.2% in the 1st quarter. Mizuho Markets Americas LLC now owns 456,636 shares of the biopharmaceutical company's stock worth $18,576,000 after acquiring an additional 9,975 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Stock Down 0.1 %

HALO traded down $0.05 on Friday, reaching $49.25. The company's stock had a trading volume of 789,585 shares, compared to its average volume of 1,431,939. The company has a market capitalization of $6.24 billion, a price-to-earnings ratio of 19.09, a P/E/G ratio of 0.50 and a beta of 1.27. Halozyme Therapeutics, Inc. has a fifty-two week low of $32.95 and a fifty-two week high of $65.53. The company has a quick ratio of 6.21, a current ratio of 7.41 and a debt-to-equity ratio of 5.19. The stock has a 50 day moving average of $57.99 and a two-hundred day moving average of $51.67.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.18. Halozyme Therapeutics had a net margin of 38.62% and a return on equity of 195.80%. The business had revenue of $231.40 million during the quarter, compared to analysts' expectations of $204.94 million. During the same quarter in the prior year, the business posted $0.68 EPS. The company's revenue for the quarter was up 4.7% on a year-over-year basis. As a group, analysts forecast that Halozyme Therapeutics, Inc. will post 3.71 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

HALO has been the subject of several research reports. HC Wainwright reiterated a "buy" rating and issued a $65.00 target price on shares of Halozyme Therapeutics in a report on Friday. Wells Fargo & Company downgraded Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and boosted their price objective for the company from $58.00 to $62.00 in a report on Monday, October 7th. TD Cowen increased their target price on Halozyme Therapeutics from $59.00 to $65.00 and gave the stock a "buy" rating in a research note on Wednesday, August 7th. JPMorgan Chase & Co. downgraded Halozyme Therapeutics from an "overweight" rating to a "neutral" rating and lifted their target price for the company from $52.00 to $57.00 in a research report on Thursday, September 19th. Finally, Benchmark reissued a "buy" rating and set a $60.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, August 8th. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, Halozyme Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $60.44.

Insiders Place Their Bets

In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $59.20, for a total transaction of $592,000.00. Following the transaction, the chief executive officer now owns 676,744 shares of the company's stock, valued at $40,063,244.80. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, CEO Helen Torley sold 10,000 shares of the company's stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $59.20, for a total value of $592,000.00. Following the completion of the sale, the chief executive officer now owns 676,744 shares in the company, valued at $40,063,244.80. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Matthew L. Posard sold 9,881 shares of the firm's stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $57.70, for a total transaction of $570,133.70. Following the transaction, the director now directly owns 69,874 shares in the company, valued at $4,031,729.80. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 89,881 shares of company stock valued at $5,169,834. 2.40% of the stock is currently owned by insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.